114 related articles for article (PubMed ID: 5296733)
1. [Protease activity in shock. Indications for Trasylol-R therapy].
Halvorsen KA
Tidsskr Nor Laegeforen; 1966 May; 86(9):681-3. PubMed ID: 5296733
[No Abstract] [Full Text] [Related]
2. [Trasylol in the shock therapy. Its effects and their interpretation].
Haberland GL; Koslowski L; Matis P
Med Welt; 1972 Aug; 23(31):1049-56. PubMed ID: 4539608
[No Abstract] [Full Text] [Related]
3. [Effect of a protease inhibitor on the Tourniquet syndrome in the rat. II. Improvement of survival time in Tourniquet-shock by Trasylol].
Stock W; Eigler FW
Z Gesamte Exp Med Einschl Exp Chir; 1969 Sep; 151(1):64-73. PubMed ID: 5308803
[No Abstract] [Full Text] [Related]
4. Role of a myocardial depressant factor in shock states.
Lefer AM
Mod Concepts Cardiovasc Dis; 1973 Dec; 42(12):59-64. PubMed ID: 4205659
[No Abstract] [Full Text] [Related]
5. [Proteinase inhibition in shock therapy. Colloquium September 7, 1973 at Cologne].
Matis P
Med Welt; 1973 Dec; 24(49):1963-5. PubMed ID: 4544302
[No Abstract] [Full Text] [Related]
6. Prophylaxis of post-traumatic pulmonary insufficiency by protease-inhibitor therapy with aprotinin: a clinical study.
McMichan JC; Rosengarten DS; Philipp E
Circ Shock; 1982; 9(2):107-16. PubMed ID: 6177441
[No Abstract] [Full Text] [Related]
7. [Antishock effects of trasylol and its protective effects on open heart surgery (author's transl)].
Suemori I; Yoshitake J
Kokyu To Junkan; 1976 May; 24(5):441-6. PubMed ID: 1084005
[No Abstract] [Full Text] [Related]
8. [Field study on the therapeutic value of trasylol in traumatic shock].
Schneider B; Schnells G; Trentz O; Tscherne H
Chirurg; 1976 Apr; 47(4):185-8. PubMed ID: 1085692
[TBL] [Abstract][Full Text] [Related]
9. [Tourniquet-schock following treatment with streptase, prednisolone and trasylol. Pathologic-anatomic findings].
Schubert GE; Durst J; Rahmer H
Med Welt; 1977 Jul; 28(27):1190-4. PubMed ID: 301980
[No Abstract] [Full Text] [Related]
10. [Intensive therapy of shock, especially using proteinase inhibitors].
Zimmerman WE
Med Welt; 1975 Aug; 26(33-34):1478-9. PubMed ID: 1080829
[No Abstract] [Full Text] [Related]
11. [Current aspects of enzyme-inhibitory therapy].
Stoimenov G; Doĭchinov Al
Akush Ginekol (Sofiia); 1971; 10(1):86-7. PubMed ID: 5316428
[No Abstract] [Full Text] [Related]
12. [The role of proteolytic enzymes and the use of trasylol in burns].
Koslowski L
Med Welt; 1968 Dec; 52():2853-6. PubMed ID: 5304892
[No Abstract] [Full Text] [Related]
13. [Trasylol R on the status of experimental shock (preliminary results)].
Back N; Wilkens H; Munson AE; Steger R
Rev Bras Med; 1968 Jun; 25(6):410-5. PubMed ID: 5304846
[No Abstract] [Full Text] [Related]
14. [Trasylol--its action and use].
Kwiatkowska-Dutkiewicz E
Wiad Lek; 1970 Oct; 23(20):1773-6. PubMed ID: 4921399
[No Abstract] [Full Text] [Related]
15. [Comparative assessment of the therapeutic effect of inhitryl in tourniquet shock (experimental study)].
Kharchenko VZ; Protsenko VA; Usharovich SM
Farmakol Toksikol; 1977; 40(2):187-90. PubMed ID: 300691
[No Abstract] [Full Text] [Related]
16. [Clinical use of natural kallikrein-protease inhibitors].
Sudneva LI
Klin Med (Mosk); 1981 Jun; 59(6):8-12. PubMed ID: 6169874
[No Abstract] [Full Text] [Related]
17. [The therapy of acute autodigestive pancreatitis in relation to the time factor].
Mättig H; Clauss D
Zentralbl Chir; 1967 Nov; 92(45):2811-8. PubMed ID: 5301814
[No Abstract] [Full Text] [Related]
18. [Role of protease in the pathogenesis of shock].
Ogawa R; Imai T; Uchida K; Fujita T
Masui; 1974 Mar; 23(3):207-13. PubMed ID: 4546495
[No Abstract] [Full Text] [Related]
19. [Proteolytic enzymes and their inhibitors in clinical and experimental oncology].
Geshelin SA; Vovchuk SV; Blizniuk BF; Varbanets VF
Vopr Onkol; 1984; 30(10):9-18. PubMed ID: 6208687
[No Abstract] [Full Text] [Related]
20. [Antiproteases: classical indications, new use].
Bel MA
J Med Lyon; 1970 Dec; 51(199):2199-217. PubMed ID: 5317232
[No Abstract] [Full Text] [Related]
[Next] [New Search]
